P-cadherin linking breast cancer stem cells and invasion: A promising marker to identify an "intermediate/metastable" EMT state

Frontiers in Oncology

Volumn 4, Issue , 2015, Pages

  Ribeiro, Ana Sofia ^a   Paredes, Joana ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

Author keywords

Breast cancer; EMT transition; Metastable phenotype; Metastasis; P cadherin

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; ALPHA6 INTEGRIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUCOSE TRANSPORTER 1; HERMES ANTIGEN; HUMAN MONOCLONAL ANTIBODY; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MATRIX METALLOPROTEINASE; NERVE CELL ADHESION MOLECULE; P CADHERIN; PEPTIDES AND PROTEINS; PF 03732010; TRANSCRIPTION FACTOR FOXC2; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR ZEB1; TRANSCRIPTION FACTOR ZEB2; UNCLASSIFIED DRUG; UVOMORULIN;

ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER STEM CELL; CARCINOGENESIS; EMBRYO DEVELOPMENT; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; PHENOTYPE; RECURRENCE FREE SURVIVAL; TISSUE DIFFERENTIATION; TUMOR INVASION;

EID: 85018189090     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00371     Document Type: Article

References (64)

1. Klymkowsky MW, Savagner P. Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe. Am J Pathol (2009) 174:1588-93. doi:10.2353/ajpath.2009.080545
2. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer (2009) 9:265-73. doi:10.1038/nrc2620
3. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell (2009) 139:871-90. doi:10.1016/j.cell. 2009.11.007
4. Yilmaz M, Christofori G. Emt, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev (2009) 28:15-33. doi:10.1007/s10555-008-9169-0
5. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA (2003) 100:8418-23. doi:10.1073/pnas.0932692100
6. Brabletz T. Emt and met in metastasis: where are the cancer stem cells? Cancer Cell (2012) 22:699-701. doi:10.1016/j.ccr.2012.11.009
7. Carstens JL, Lovisa S, Kalluri R. Microenvironment-dependent cues trigger mirna-regulated feedback loop to facilitate the emt/met switch. J Clin Invest (2014) 124:1458-60. doi:10.1172/JCI75239
8. Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene (2008) 27:6920-9. doi:10.1038/ onc.2008.343
9. Han SP, Yap AS. The cytoskeleton and classical cadherin adhesions. Subcell Biochem (2012) 60:111-35. doi:10.1007/978-94-007-4186-7_6
10. Brieher WM, Yap AS. Cadherin junctions and their cytoskeleton(s). Curr Opin Cell Biol (2013) 25:39-46. doi:10.1016/j.ceb.2012.10.010
11. Azmi AS. Unveiling the role of nuclear transport in epithelial-to-mesenchymal transition. Curr Cancer Drug Targets (2013) 13:906-14. doi:10.2174/ 15680096113136660096
12. Hay ED. The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it. Dev Dyn (2005) 233:706-20. doi:10.1002/ dvdy.20345
13. Zavadil J, Haley J, Kalluri R, Muthuswamy SK, Thompson E. Epithelialmesenchymal transition. Cancer Res (2008) 68:9574-7. doi:10.1158/0008-5472. CAN-08-2316
14. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol (2006) 172:973-81. doi:10.1083/jcb.200601018
15. Ksiazkiewicz M, Markiewicz A, Zaczek AJ. Epithelial-mesenchymal transition: a hallmark in metastasis formation linking circulating tumor cells and cancer stem cells. Pathobiology (2012) 79:195-208. doi:10.1159/000337106
16. Krasnapolski MA, Todaro LB, de Kier Joffe EB. Is the epithelial-to-mesenchymal transition clinically relevant for the cancer patient? Curr Pharm Biotechnol (2011) 12:1891-9. doi:10.2174/138920111798377021
17. Chaw SY, Majeed AA, Dalley AJ, Chan A, Stein S, Farah CS. Epithelial to mesenchymal transition (emt) biomarkers -e-cadherin, beta-catenin, apc and vimentin -in oral squamous cell carcinogenesis and transformation. Oral Oncol (2012) 48:997-1006. doi:10.1016/j.oraloncology.2012.05.011
18. Markiewicz A, Ahrends T, Welnicka-Jaskiewicz M, Seroczynska B, Skokowski J, Jaskiewicz J, et al. Expression of epithelial to mesenchymal transition-related markers in lymph node metastases as a surrogate for primary tumor metastatic potential in breast cancer. J Transl Med (2012) 10:226. doi:10.1186/1479-5876-10-226
19. Li G, Herlyn M. Dynamics of intercellular communication during melanoma development. Mol Med Today (2000) 6:163-9. doi:10.1016/S1357-4310(00) 01692-0
20. Tomita K, van Bokhoven A, van Leenders GJ, Ruijter ET, Jansen CF, Bussemakers MJ, et al. Cadherin switching in human prostate cancer progression. Cancer Res (2000) 60:3650-4.
21. Bailey T, Biddlestone L, Shepherd N, Barr H, Warner P, Jankowski J. Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasiaadenocarcinoma sequence: correlation with disease progression and dedifferentiation. Am J Pathol (1998) 152:135-44.
22. de Boer CJ, van Dorst E, van Krieken H, Jansen-van Rhijn CM, Warnaar SO, Fleuren GJ, et al. Changing roles of cadherins and catenins during progression of squamous intraepithelial lesions in the uterine cervix. Am J Pathol (1999) 155:505-15. doi:10.1016/S0002-9440(10)65146-2
23. Patel IS, Madan P, Getsios S, Bertrand MA, MacCalman CD. Cadherin switching in ovarian cancer progression. Int J Cancer (2003) 106:172-7. doi:10.1002/ ijc.11086
24. Lim J, Thiery JP. Epithelial-mesenchymal transitions: insights from development. Development (2012) 139:3471-86. doi:10.1242/dev.071209
25. Chu PY, Hu FW, Yu CC, Tsai LL, Yu CH, Wu BC, et al. Epithelial-mesenchymal transition transcription factor zeb1/zeb2 co-expression predicts poor prognosis and maintains tumor-initiating properties in head and neck cancer. Oral Oncol (2013) 49:34-41. doi:10.1016/j.oraloncology.2012.07.012
26. Guo J,Fu Z,Wei J,Lu W,Feng J,Zhang S. Prrx1 promotes epithelial-mesenchymal transition through the wnt/beta-catenin pathway in gastric cancer. Med Oncol (2015) 32:393. doi:10.1007/s12032-014-0393-x
27. Ivaska J. Vimentin: central hub in emt induction? Small GTPases (2011) 2:51-3. doi:10.4161/sgtp.2.1.15114
28. Ivaska J, Heino J. Cooperation between integrins and growth factor receptors in signaling and endocytosis. Annu Rev Cell Dev Biol (2011) 27:291-320. doi:10.1146/annurev-cellbio-092910-154017
29. Kaufhold S, Bonavida B. Central role of snail1 in the regulation of emt and resistance in cancer: a target for therapeutic intervention. J Exp Clin Cancer Res (2014) 33:62. doi:10.1186/s13046-014-0062-0
30. Liu AN, Zhu ZH, Chang SJ, Hang XS. Twist expression associated with the epithelial-mesenchymal transition in gastric cancer. Mol Cell Biochem (2012) 367:195-203. doi:10.1007/s11010-012-1333-8
31. Paredes J, Albergaria A, Oliveira JT, Jeronimo C, Milanezi F, Schmitt FC. Pcadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with cdh3 promoter hypomethylation. Clin Cancer Res (2005) 11:5869-77. doi:10.1158/1078-0432.CCR-05-0059
32. Ribeiro AS, Sousa B, Carreto L, Mendes N, Nobre AR, Ricardo S, et al. P-cadherin functional role is dependent on e-cadherin cellular context: a proof of concept using the breast cancer model. J Pathol (2013) 229:705-18. doi:10.1002/path.4143
33. Gamallo C, Moreno-Bueno G, Sarrio D, Calero F, Hardisson D, Palacios J. The prognostic significance of p-cadherin in infiltrating ductal breast carcinoma. Mod Pathol (2001) 14:650-4. doi:10.1038/modpathol.3880367
34. Peralta Soler A, Knudsen KA, Salazar H, Han AC, Keshgegian AA. Pcadherin expression in breast carcinoma indicates poor survival. Cancer (1999) 86:1263-72. doi:10.1002/(SICI)1097-0142(19991001)86:77<1263::AIDCNCR23>3.0.CO;2-2
35. Turashvili G, McKinney SE, Goktepe O, Leung SC, Huntsman DG, Gelmon KA, et al. P-cadherin expression as a prognostic biomarker in a 3992 case tissue microarray series of breast cancer. Mod Pathol (2011) 24:64-81. doi:10.1038/modpathol.2010.189
36. Liu N,Yu Q, Liu TJ, Gebreamlak EP, Wang SL, Zhang RJ, et al. P-cadherin expression and basal-like subtype in breast cancers. Med Oncol (2012) 29:2606-12. doi:10.1007/s12032-012-0218-8
37. Sousa B, Paredes J, Milanezi F, Lopes N, Martins D, Dufloth R, et al. P-cadherin, vimentin and ck14 for identification of basal-like phenotype in breast carcinomas: an immunohistochemical study. Histol Histopathol (2010) 25:963-74.
38. Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol (2011) 24:157-67. doi:10.1038/modpathol.2010.200
39. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature (2000) 406:747-52. doi:10.1038/35021093
40. Cheung LW, Leung PC, Wong AS. Cadherin switching and activation of p120 catenin signaling are mediators of gonadotropin-releasing hormone to promote tumor cell migration and invasion in ovarian cancer. Oncogene (2010) 29:2427-40. doi:10.1038/onc.2009.523
41. Kumper S, Ridley AJ. P120ctn and p-cadherin but not e-cadherin regulate cell motility and invasion of du145 prostate cancer cells. PLoS One (2010) 5:e11801. doi:10.1371/journal.pone.0011801
42. Mandeville JA, Silva Neto B, Vanni AJ, Smith GL, Rieger-Christ KM, Zeheb R, et al. P-cadherin as a prognostic indicator and a modulator of migratory behaviour in bladder carcinoma cells. BJU Int (2008) 102:1707-14. doi:10.1111/j.1464-410X.2008.08115.x
43. Paredes J, Correia AL, Ribeiro AS, Albergaria A, Milanezi F, Schmitt FC. Pcadherin expression in breast cancer: a review. Breast Cancer Res (2007) 9:214. doi:10.1186/bcr1774
44. Paredes J, Stove C, Stove V, Milanezi F, Van Marck V, Derycke L, et al. Pcadherin is up-regulated by the antiestrogen ici 182,780 and promotes invasion of human breast cancer cells. Cancer Res (2004) 64:8309-17. doi:10.1158/0008-5472.CAN-04-0795
45. Ribeiro AS, Albergaria A, Sousa B, Correia AL, Bracke M, Seruca R, et al. Extracellular cleavage and shedding of p-cadherin: a mechanism underlying the invasive behaviour of breast cancer cells. Oncogene (2010) 29:392-402. doi:10.1038/onc.2009.338
46. Taniuchi K, Nakagawa H, Hosokawa M, Nakamura T, Eguchi H, Ohigashi H, et al. Overexpressed p-cadherin/cdh3 promotes motility of pancreatic cancer cells by interacting with p120ctn and activating rho-family gtpases. Cancer Res (2005) 65:3092-9. doi:10.1158/0008.5472.CAN-04-3646
47. Mannello F, Tonti GA, Medda V, Pederzoli A, Sauter ER. Increased shedding of soluble fragments of p-cadherin in nipple aspirate fluids from women with breast cancer. Cancer Sci (2008) 99:2160-9. doi:10.1111/j.1349-7006.2008. 00921.x
48. Ben Hamida A, Labidi IS, Mrad K, Charafe-Jauffret E, Ben Arab S, Esterni B, et al. Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of p-cadherin. BMC Cancer (2008) 8:28. doi:10.1186/1471-2407-8-28
49. Cheung LW, Mak AS, Cheung AN, Ngan HY, Leung PC, Wong AS. P-cadherin cooperates with insulin-like growth factor-1 receptor to promote metastatic signaling of gonadotropin-releasing hormone in ovarian cancer via p120 catenin. Oncogene (2011) 30:2964-74. doi:10.1038/onc.2011.7
50. Bauer K, Dowejko A, Bosserhoff AK, Reichert TE, Bauer RJ. P-cadherin induces an epithelial-like phenotype in oral squamous cell carcinoma by gsk-3betamediated snail phosphorylation. Carcinogenesis (2009) 30:1781-8. doi:10.1093/ carcin/bgp175
51. Sarrio D, Palacios J, Hergueta-Redondo M, Gomez-Lopez G, Cano A, MorenoBueno G. Functional characterization of e-and p-cadherin in invasive breast cancer cells. BMC Cancer (2009) 9:74. doi:10.1186/1471-2407-9-74
52. Van Marck V, Stove C, Van Den Bossche K, Stove V, Paredes J, Vander Haeghen Y, et al. P-cadherin promotes cell-cell adhesion and counteracts invasion in human melanoma. Cancer Res (2005) 65:8774-83. doi:10.1158/0008-5472. CAN-04-4414
53. Paredes J, Correia AL, Ribeiro AS, Milanezi F, Cameselle-Teijeiro J, Schmitt FC. Breast carcinomas that co-express e-and p-cadherin are associated with p120-catenin cytoplasmic localisation and poor patient survival. J Clin Pathol (2008) 61:856-62. doi:10.1136/jcp.2007.052704
54. Schmitt F, Ricardo S, Vieira AF, Dionisio MR, Paredes J. Cancer stem cell markers in breast neoplasias: their relevance and distribution in distinct molecular subtypes. Virchows Arch (2012) 460:545-53. doi:10.1007/s00428-012-1237-8
55. Visvader JE. Cells of origin in cancer. Nature (2011) 469:314-22. doi:10.1038/ nature09781
56. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelialmesenchymal transition generates cells with properties of stem cells. Cell (2008) 133:704-15. doi:10.1016/j.cell.2008.03.027
57. Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One (2008) 3:e2888. doi:10.1371/journal.pone.0002888
58. Ablett MP, Singh JK, Clarke RB. Stem cells in breast tumours: are they ready for the clinic? Eur J Cancer (2012) 48:2104-16. doi:10.1016/j.ejca.2012.03.019
59. Vieira AF, Ricardo S, Ablett MP, Dionisio MR, Mendes N, Albergaria A, et al. Pcadherin is coexpressed with cd44 and cd49f and mediates stem cell properties in basal-like breast cancer. Stem Cells (2012) 30:854-64. doi:10.1002/stem.1075
60. Nassour M, Idoux-Gillet Y, Selmi A, Come C, Faraldo ML, Deugnier MA, et al. Slug controls stem/progenitor cell growth dynamics during mammary gland morphogenesis. PLoS One (2012) 7:e53498. doi:10.1371/journal.pone.0053498
61. Vieira AF, Ribeiro AS, Dionisio MR, Sousa B, Nobre AR, Albergaria A, et al. Pcadherin signals through the laminin receptor alpha6beta4 integrin to induce stem cell and invasive properties in basal-like breast cancer cells. Oncotarget (2014) 5:679-92.
62. Ricardo S, Vieira AF, Gerhard R, Leitao D, Pinto R, Cameselle-Teijeiro JF, et al. Breast cancer stem cell markers cd44, cd24 and aldh1: expression distribution within intrinsic molecular subtype. J Clin Pathol (2011) 64:937-46. doi:10.1136/jcp.2011.090456
63. Sousa B, Ribeiro AS, Nobre AR, Lopes N, Martins D, Pinheiro C, et al. The basal epithelial marker p-cadherin associates with breast cancer cell populations harboring a glycolytic and acid-resistant phenotype. BMC Cancer (2014) 14:734. doi:10.1186/1471-2407-14-734
64. Zhang CC, Yan Z, Zhang Q, Kuszpit K, Zasadny K, Qiu M, et al. Pf-03732010: a fully human monoclonal antibody against p-cadherin with antitumor and antimetastatic activity. Clin Cancer Res (2010) 16:5177-88. doi:10.1158/1078-0432.CCR-10-1343